Another investigation showed that inhibition of BCKDK by siRNA or chemical inhibitors could reduce BCAA levels and synergistically induce the antitumor effects of paclitaxel in breast and ovarian cancer cells. The gene discussed is BCKDK; the disease is ovarian carcinoma.